We tested the therapeutic potential of a recently developed highly selective (10,000-fold selectivity over other subtypes of adenosine receptors) A3AR agonist, MRS5980 [21], in our well-established mouse model of cisplatin-induced cognitive deficits and peripheral neuropathy [7, 8, 26, 36]. Here, ADORA3 is linked to peripheral neuropathy.